Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma

被引:24
作者
Konishi, N
Nakamura, M
Kishi, M
Ishida, E
Shimada, K
Matsuyoshi, S
Nagai, H
Emi, M
机构
[1] Nara Med Univ, Dept Pathol, Nara 6348521, Japan
[2] Nippon Med Coll, Inst Gerontol, Dept Mol Biol, Nakahara Ku, Kanagawa 2118533, Japan
关键词
D O I
10.1111/j.1349-7006.2003.tb01516.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A number of genetic events have been reported in prostate carcinogenesis, including frequent loss of heterozygosity (LOH) on chromosomes 8q, 10q, 16q and 18q. In samples of heterogeneous, multifocal prostate carcinomas, we focused on chromosome 6q using PCR-based techniques with 15 microsatellite markers to identify the specific 6q deletion within tumors. LOH of one or more polymorphic markers was detected in 10 of 21 tumors (48%). Two of these 10 tumors demonstrated LOH in all cancerous foci at specific loci and 4 tumors showed deletion in one focus. Different deletion patterns were found in 3 tumors when different polymorphic markers were used. In 90% of tumors showing LOH in one or more foci, however, two common regions of LOH were identified; one at 1.81 cM on 6q15-16.3 between markers D6S1631 and D6S1056, and the other at 5.11 cM on 6q16-21 between markers D6S424 and D6S283. By RT-PCR analysis, the TAK1 gene located at these loci did not correlate with LOH status, indicating that TAK1 is not a target gene in prostate carcinoma. The 6q deletion occurs heterogeneously and LOH was more frequent in tumors of higher pathological stages, implying that this alteration is a late event in prostate carcinogenesis. Because prostate carcinomas are genetically multicentric and of multifocal origin, it remains unclear whether the foci containing 6q deletions specifically expand within tumors or to what extent they contribute to the histological heterogeneity characteristic of the disease.
引用
收藏
页码:764 / 768
页数:5
相关论文
共 40 条
[1]   Identification of genetic markers for prostatic cancer progression [J].
Alers, JC ;
Rochat, J ;
Krijtenburg, PJ ;
Hop, WCJ ;
Kranse, R ;
Rosenberg, C ;
Tanke, HJ ;
Schröder, FH ;
van Dekken, H .
LABORATORY INVESTIGATION, 2000, 80 (06) :931-942
[2]  
An G, 2000, CANCER RES, V60, P7014
[3]  
[Anonymous], 1997, AJCC CANC STAGING MA
[4]   Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin [J].
Berggren, MI ;
Husbeck, B ;
Samulitis, B ;
Baker, AF ;
Gallegos, A ;
Powis, G .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 392 (01) :103-109
[5]   Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors [J].
Bilanges, B ;
Varrault, A ;
Basyuk, E ;
Rodriguez, C ;
Mazumdar, A ;
Pantaloni, C ;
Bockaert, J ;
Theillet, C ;
Spengler, D ;
Journot, L .
ONCOGENE, 1999, 18 (27) :3979-3988
[6]  
BOSTWICK DG, 1995, CANCER-AM CANCER SOC, V75, P1823, DOI 10.1002/1097-0142(19950401)75:7+<1823::AID-CNCR2820751612>3.0.CO
[7]  
2-7
[8]  
Bostwick DG, 1996, PROSTATE, V29, P117
[9]   Evidence of independent origin of multiple tumors from patients with prostate cancer [J].
Cheng, L ;
Song, SY ;
Pretlow, TG ;
Abdul-Karim, FW ;
Kung, HJ ;
Dawson, DV ;
Park, WS ;
Moon, YW ;
Tsai, ML ;
Linehan, WM ;
Emmert-Buck, MR ;
Liotta, LA ;
Zhuang, ZP .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (03) :233-237
[10]  
Cher ML, 1996, CANCER RES, V56, P3091